Prothena Corporation PLC
PRTA
View Detailed Chart
9.260USD
-0.260-2.73%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
498.49MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.73%
5 Days
+5.83%
1 Month
+6.81%
6 Months
-1.59%
Year to Date
-3.04%
1 Year
-29.53%
View Detailed Chart
TradingKey Stock Score of Prothena Corporation PLC
Currency: USD Updated: 2026-03-27Key Insights
Prothena Corporation PLC's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 110 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 21.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prothena Corporation PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Prothena Corporation PLC Highlights
StrengthsRisks
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.68M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.68M.
Overvalued
The company’s latest PE is -2.04, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 43.35M shares, decreasing 31.25% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 435.51K shares of this stock.
Analyst Rating
Based on
6
analysts
Hold
Current Rating
21.000
Target Price
+120.59%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Prothena Corporation PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Prothena Corporation PLC Info
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Ticker SymbolPRTA
CompanyProthena Corporation PLC
CEOKinney (Gene G)
Websitehttps://www.prothena.com/
Related Instruments
-2.10%
-1.92%
+0.49%
+2.48%
+0.58%
-0.88%
-0.98%
-1.24%
-0.51%
-1.96%
-1.02%
+0.34%
-0.19%
-1.55%
-4.56%
0.00%
-0.55%
-2.51%
-2.86%
-0.83%Popular Symbols
248.800
-4.090 (-1.62%)
167.520
-3.720 (-2.17%)
66289.760
-586.240 (-0.88%)
275.340
+1.990 (+0.73%)
1990.690
-31.400 (-1.55%)
361.830
-10.280 (-2.76%)
4492.520
+112.460 (+2.57%)
100.609
+7.287 (+7.81%)
1.151
-0.002 (-0.17%)
160.252
+0.465 (+0.29%)
